Brazil boasts world-class biomedical science, but tension between the public and private sectors hinders progress in health biotech innovation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators
Health Research Policy and Systems Open Access 06 June 2012
-
Science-based health innovation in sub-Saharan Africa
BMC International Health and Human Rights Open Access 13 December 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
World Health Organization. Demographic and Socioeconomic Statistics, (WHO, Geneva, 2005). <http://www.who.int/healthinfo/statistics/ whostat2005_demosocio_en.pdf> Accessed April 15, 2008.
Thorsteinsdöttir, H., Quach, U., Martin, D., Daar, A.S. & Singer, P.A. Health biotechnology innovation in developing countries. Nat. Biotechnol., Suppl DC1–DC22 (2004).
Ferrer, M., Thorsteinsdöttir, H., Quach, U., Singer, P.A. & Daar, A.S. The scientific muscle of Brazil's health biotechnology. Nat. Biotechnol. 22 Suppl, DC8–DC12 (2004).
Frew, S.E. et al. India's health biotech sector at a crossroads. Nat. Biotechnol. 25, 403–417 (2007).
Frew, S.E. et al. Chinese health biotech and the billion-patient market. Nat. Biotechnol. 26, 37–53 (2008).
Policy Brief, O.E.C.D. Economic Survey of Brazil, 2006. (Organization For Economic Co-Operation And Development, Paris, 2006) <http://www.oecd.org/dataoecd/47/47/37667205.pdf> Accessed September 10, 2007)
Bonalume Neto, R. Brazil next biotech trailblazer in Latin America? Nat. Biotechnol. 24, 1184 (2006).
FAPESP. Translating Research into Business; Ten Years Promoting Technological Innovation. (The State of São Paulo Research Foundation, São Paulo, 2005) <http://www.fapesp.br/publicacoes/fichas_inovacao_en.pdf> Accessed, April 15, 2008.
Organization For Economic Co-Operation And Development. OECD in Figures, 2007 Edition. (OECD, Paris, 2007). <http://oberon.sourceoecd.org/pdf/figures_2007/en/oif.pdf> Accessed: April 19, 2008.
World Health Organization. Immunization Profile - Brazil. (WHO, Geneva, 2007) <http://www.who.int/vaccines/globalsummary/ immunization/countryprofileresult.cfm?C='bra'> Accessed September 2, 2007.
Report, P. Pharmaceuticals and Healthcare Report Q3 2006. (2006). <http://www.piribo.com/publications/country/latin_america/brazil/ brazil_pharmaceuticals_healthcare_report_q3_2006.html> Accessed September 12, 2007.
Basso, M. Intervention of health authorities in patent examination: the Brazilian practice of the prior consent. Int. J. Intellectual Property Management 1, 54–74 (2006).
Peer, M. Patients over patents, says Brazil health ministry (April 10, 2008). <http://www.forbes.com/markets/2008/04/10/gilead-sciences-closer-markets-equity-cx_mp_0410markets44.html> Accessed April 18, 2008.
Cardoso, T.A.O. et al. Memories of biotechnology in Brazil: lessons to be learned. Applied Biosafety 10, 160–168 (2005).
Rohter, L. In Brazil, a conviction on biopiracy charges angers scientists. International Herald Tribune (August 29, 2007).<http://www.iht.com/articles/2007/08/29/healthscience/ snbiopiracy.php>
Quezada, F. Status and Potential of Commercial Bioprospecting Activities in Latin America and the Caribbean. (United Nations Publications, New York, 2007).
Marques, R. The Brazilian system of innovation in biotechnology: a preliminary study. J. Technol. Manag. Innov. 2, 55–63 (2007).
Guimarães, J.A. & Humann, M.C. Training of human resources in science and technology in Brazil: the importance of a vigorous post-graduate program and its impact on the development of the country. Scientometrics 34, 101–119 (1995).
Leta, J., Glänzel, W. & Thijs, B. Science in Brazil. Part 2: sectoral and institutional research profiles. Scientometrics 67, 87–105 (2006).
Business, D. In Brazil. (British Chamber of Commerce Publication, São Paulo, Brazil, 2005).
Medical News Today. Brazilian President Silva issues compulsory license for Merck's antiretroviral efavirenz (May 9, 2007). <http://www.medicalnewstoday.com/articles/70154.php> Accessed August 24, 2007.
Okie, S. Fighting HIV–lessons from Brazil. N. Engl. J. Med. 354, 1977–1981 (2006).
Joint UNAIDS/WHO Report. Latin America Aids Epidemic Update, Regional Summary. (2007) <http://data.unaids.org/pub/Report/2008/ jc1530_epibriefs_latinamerica_en.pdf> Accessed April 16, 2008.
Grangeiro, A., Teixeira, L., Bastos, F.I. & Teixeira, P. Sustainability of Brazilian Policy for Access to Antiretroviral Drugs. Rev. Saude Publica 40 Suppl., 60–69 (2006).
Espicom Business Intelligence Report. The Outlook for Pharmaceuticals in Latin America to 2012; Gearing Towards Global Competitiveness? (July 31, 2007). <https://www.espicom.com/prodcat.nsf/Product_ID_Lookup/ 00000395?OpenDocument> Accessed October 22, 2007.
Acknowledgements
We gratefully acknowledge Halla Thorsteinsdottir, Ana Lucia Delgado Assad, William Marandola, Eduardo Emrich Soares and Joao de S.B. Paes de Carvalho for their assistance and guidance. We also acknowledge the valuable comments of Christopher Earl, Charles Gardner, Mario Gobbo, Hannah Kettler, Marsha Wulff and Andrew Taylor in shaping the overall study design, and Billie-Jo Hardy for her editorial assistance. The McLaughlin-Rotman Centre for Global Health, Program on Life Sciences, Ethics and Policy is primarily supported by Genome Canada through the Ontario Genomics Institute and the Ontario Research Fund, and the Bill and Melinda Gates Foundation. This study is also funded by the Rockefeller Foundation (New York) and BioVentures for Global Health (Washington, DC, USA), and through in-kind contributions from Burrill & Company (San Francisco) and Wulff Capital (Dallas). Other matching partners are listed at http://www.mrcglobal.org/. A.S.D. and P.A.S. are supported by the McLaughlin Centre for Molecular Medicine. P.A.S. is supported by a Canadian Institutes of Health Research Distinguished Investigator award.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
P.A.S. is a member of the Industrial Policy Advisory Committee of Merck Frosst Canada and in the past has received research funds from Merck & Co. He also serves on the Scientific Advisory Board of BioVeda Fund II in China. Stephen M. Sammut is affiliated with Burrill & Co., an international biotechnology venture capital firm, but which currently has no activities in Latin America.
Supplementary information
Supplementary Text and Figures
Supplementary Methods (PDF 15 kb)
Rights and permissions
About this article
Cite this article
Rezaie, R., Frew, S., Sammut, S. et al. Brazilian health biotech—fostering crosstalk between public and private sectors. Nat Biotechnol 26, 627–644 (2008). https://doi.org/10.1038/nbt0608-627
Issue Date:
DOI: https://doi.org/10.1038/nbt0608-627
This article is cited by
-
Design, fabrication and characterization of xanthan gum/liquid-loaded porous natural rubber film
Journal of Pharmaceutical Investigation (2019)
-
Access to new technologies in multipatented vaccines: challenges for Brazil
Nature Biotechnology (2015)
-
Life sciences venture capital in emerging markets
Nature Biotechnology (2013)
-
Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators
Health Research Policy and Systems (2012)
-
Innovative drugs and vaccines in China, India and Brazil
Nature Biotechnology (2012)